A Phase 1 First-in-Human, Drug-dose Escalation Study of RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced Cutaneous Squamous Cell Carcinoma or With Head and Neck Squamous Cell Carcinoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 24 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RM-1995 (Primary) ; Pembrolizumab
Indications Carcinoma; Head and neck cancer; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors Rakuten Medical

Most Recent Events

14 Apr 2023 Planned End Date changed from 1 Sep 2024 to 30 Jan 2023.
14 Apr 2023 Planned primary completion date changed from 1 Jul 2024 to 30 Jan 2023.
14 Apr 2023 Status changed from recruiting to withdrawn prior to enrolment.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight